Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy

Abstract excerpt

Background: Currently available prognostic tools and focused therapeutic methods result in unsatisfactory treatment of gastric cancer (GC). A deeper understanding of human epidermal growth factor receptor 2 (HER2)-coexpressed metabolic pathways may offer novel insights into tumour-intrinsic precision medicine. Methods: The integrated multi-omics strategies (including transcriptomics, proteomics and metabolomics)...

Topics

Join the communities discussing this publication.

• Cancer, Hypoxia, and Metabolism
• Ferroptosis and cancer prognosis
• Metabolomics and Mass Spectrometry Studies